

The role of the 2016 CDC Guideline for *Prescribing Opioids for Chronic Pain* in addressing patients on long-term opioid therapy

Debbie Dowell, MD, MPH – Chief Medical Officer CDC National Center for Injury Prevention and Control

Patient-Centered Approach to Chronic Opioid Management August 9, 2019



Morbidity and Mortality Weekly Report March 18, 2016

CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016



Continuing Education Examination available at http://www.cdc.gov/mmwr/cme/conted.html.



U.S. Department of Health and Human Services Centers for Disease Control and Prevention

Special Communication

CDC Guideline for Prescribing Opioids for Chronic Pain– United States, 2016

Deborah Dowell, MD, MPH; Tamara M. Haegerich, PhD; Roger Chou, MD

IMPORTANCE Primary care clinicians find managing chronic pain challenging. Evidence of long-term efficacy of opioids for chronic pain is limited. Opioid use is associated with serious risks, including opioid use disorder and overdose.

OBJECTIVE To provide recommendations about opicid prescribing for primary care clinicians treating adult patients with chronic pain outside of active cancer treatment, pallative care, and end-of-life care.

PBRCESS: The Centers For Disease Centrol and Prevention (CDC) updated a 2014 systematic review on effectiveness and risks of opioids and conducted a supplemental review on benefits and harms. Values and preferences, and costs. CDC used the Grading of Recommendations Assessment, Development, and Evaluation (GRADE) framework to assess evidence type and determine the recommendation category.

EVICINEC SYNTHESIS Evidence consisted of observational studies or randomized clinical trials with notable limitations, characteriods as low quality using GRADE methodology. Meta-analysis was not attampted due to the limited number of studies, variability in study designs and clinical hiereogeneity, and methodological shortcomings of studies. No study evaluated long term (-1) year bonefit of coulds for chorne pairs), lookids were associated with increased risks, including opicids use disorder, overdose, and death, with done-dependent effects.

ECOMMENDIONS There are Disconnendations Of primary importance, nanopioid heavys is performed for transment of chronic pain. Opcids shaulds but sude only when benefits for pain and shared to ransment of chronic pain. Opcids shaulds will be discontinued and but shared and an expected to cartweigh risks. Before starting oppids, clinicians should prescribe that shares and an expected share and an expected share and shares and an expected shares and an expected shares and and the shares and the shares and the shares and prescribe the shares of the shares and the shares of continued opid therapy with paties shares and shares and prescription drug monitoring program data, when available for high-risk combinators or dogues. For patient with opidial us adcounce, clinicians should prescribe and widence based treatment, such as medication-assisted treatment with buprenorphine or methadone.

CONCLUSIONS AND RELEVANCE The guideline is intended to improve communication about benefits and risks of opioids for chronic pain, improve safety and effectiveness of pain treatment, and reduce risks associated with long-term opioid therapy.

Author Affiliations: Division of Unintentional Injury Prevention National Center for Injury Prevention and Control, Centers for Desase Control and Prevention, Atlanta, Georga

Corresponding Author: Debotah Donell, MD, MPH, Dessen of Unintentional leipury Prevention, National Center for Injury Prevention and Control, Centers for Disease Control and Prevention, 4770 Budord Hwy NE, Atlanta, GA 30341 (ddowellipicd; gw).

JAMA. doi:10.1001/jama.20161464 Published online March 15, 2016 Editorials

Author Audio Interview at jama.com

Clinical Review & Education

- Related articles and JAMA Patient Page
- Supplemental content at jama.com
- Related articles at jamainternalmedicine.com, jamapediatrics.com, and jamaneurology.com

The Journal of the American Medical Association

Purpose, use, and primary audience

- Recommendations for the prescribing of opioid pain medications
 - for patients 18 and older
 - in outpatient, primary care settings
 - in treatment for chronic pain
- Not intended for use in active cancer treatment, palliative care, or end-of-life care
- Primary Audience: Primary Care Providers
 - family practice, internal medicine
 - physicians, nurse practitioners, physician assistants

CDC 2/28/19 letter to ASCO,* ASH,* and NCCN* emphasizing stated Guideline scope:

- The Guideline provides recommendations for prescribing opioids for chronic pain outside of active cancer treatment, palliative care, and end-of-life care
- Guidelines addressing pain control in sickle cell disease should be used to guide decisions
- Clinical decision-making should be based on
 - an understanding of the patient's clinical situation, functioning, and life context
 - careful consideration of the benefits and risks of all treatment options, including opioid therapy

*American Society of Clinical Oncology (ASCO), American Society of Hematology (ASH), National Comprehensive Cancer Network[®] (NCCN)

Recommendations most relevant to starting opioids

- Opioids not 1st line or routine therapy for chronic pain
- Establish and measure progress toward goals
- Discuss benefits and risks with patients before starting opioids
- Use immediate-release opioids when starting opioids
- For acute pain, 3 days or less will often be sufficient; more than 7 days will rarely be needed

Recommendations relevant to starting or continuing opioids

- Maximize use of nonopioid treatments
- Use caution when increasing dosages
 - Reassess benefits and risks of increasing dosage to ≥50 MME/day
 - Avoid or justify increasing to high dosages (<u>>90 MME/day</u>)
- Check PDMP for other prescriptions, high total dosages
- Avoid concurrent benzodiazepines and opioids
- Naloxone for patients at higher risk
- Offer or arrange medication-assisted treatment (MAT) for patients with opioid use disorder

Specific guidance for patients already receiving long-term opioid therapy

- Regularly review benefits and risks of continued opioids
- Provide interested and motivated patients with support to slowly taper opioid dosages
- Establish goals with patients who continue opioid therapy
- Maximize pain treatment with nonpharmacologic and nonopioid pharmacologic treatments

Specific guidance for patients already receiving long-term high-dose opioid therapy

- Empathetically review risks associated with continuing highdose opioids
- Offer slow taper if benefits don't outweigh risks
- For patients who agree to taper opioids to lower dosages, collaborate with the patient on a tapering plan
- Closely monitor and mitigate overdose risk for patients who continue to take high-dose opioids

Tapering guidance

- Optimize nonopioid pain management
- Taper slowly enough to minimize opioid withdrawal
- Patients tapering opioids after taking them for years might need very slow opioid tapers (e.g., 10% per month or slower)
- Individualize tapering plans based on patient goals, concerns
- Allow for pauses in the taper

Tapering guidance

- Access appropriate expertise if considering tapering opioids during pregnancy
- Discuss with patients the increased risk for overdose on abrupt return to a previously prescribed higher dose
- Remain alert to signs of anxiety, depression, and opioid use disorder that might be unmasked by an opioid taper
- Optimize psychosocial support for taper-related anxiety




TRAVIS REIDER

The agony of opioid withdrawal and what doctors should tell their patients

Rieder, Travis (2017 October). The agony of opioid withdrawal and what doctors should tell their patients. Retrieved from https://www.ted.com/talks/travis-rieder_the-agony_of_opioid_withdrawal_and_what_doctors_should_tell_patients_about_it?language=en

POCKET GUIDE: TAPERING

Follow up regularly with patients to determine whether opioids are meeting treatment goals and whether opioids can be reduced to lower dosage or discontinued.





GUIDELINE FOR PRESCRIBING OPIOIDS FOR CHRONIC PAIN

'Recommendations focus on pain lasting longer than 3 months or past the time of normal tissue healing, outside of active cancer treatment, palliative care, and end-of-life care.

CDC Guideline implementation

Focus on four priority areas to maximize the uptake and use of the opioid prescribing guideline for chronic pain outside of active cancer, palliative, & end-of-life care





Translation and Communication

Develop tools and resources about the guidelines for a variety of audiences – including providers, health systems, and the general public.

Clinical Training

Educate providers through medical schools and ongoing continuing medical education (CME) activities.



Health System Implementation

Educate providers, integrate into EHRs and other clinical decision support tools, adopt and use quality metrics, and leverage within broader coordinated care activities.



Insurer/Pharmacy Benefit Manager Implementation

Proactive improvement in coverage and service delivery payment models – including reimbursement for clinician counseling; coverage for non-pharmacological treatments and medication-assisted treatment; and drug utilization management.



The NEW ENGLAND JOURNAL of MEDICINE

"there are no shortcuts to safer opioid prescribing... or to appropriate and safe reduction or discontinuation of opioid use"

Perspective

No Shortcuts to Safer Opioid Prescribing

Deborah Dowell, M.D., M.P.H., Tamara Haegerich, Ph.D., and Roger Chou, M.D.

For more information, contact CDC 1-800-CDC-INFO (232-4636) TTY: 1-888-232-6348 www.cdc.gov

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention.

